Silumbwe Adam, Zulu Joseph Mumba, Halwindi Hikabasa, Jacobs Choolwe, Zgambo Jessy, Dambe Rosalia, Chola Mumbi, Chongwe Gershom, Michelo Charles
Department of Health Policy and Management, School of Public Health, University of Zambia, PO Box 50110, Lusaka, Zambia.
Department of Health Promotion and Education, School of Public Health, University of Zambia, PO Box 50110, Lusaka, Zambia.
BMC Public Health. 2017 May 22;17(1):484. doi: 10.1186/s12889-017-4414-5.
Understanding factors surrounding the implementation process of mass drug administration for lymphatic filariasis (MDA for LF) elimination programmes is critical for successful implementation of similar interventions. The sub-Saharan Africa (SSA) region records the second highest prevalence of the disease and subsequently several countries have initiated and implemented MDA for LF. Systematic reviews have largely focused on factors that affect coverage and compliance, with less attention on the implementation of MDA for LF activities. This review therefore seeks to document facilitators and barriers to implementation of MDA for LF in sub-Saharan Africa.
A systematic search of databases PubMed, Science Direct and Google Scholar was conducted. English peer-reviewed publications focusing on implementation of MDA for LF from 2000 to 2016 were considered for analysis. Using thematic analysis, we synthesized the final 18 articles to identify key facilitators and barriers to MDA for LF programme implementation.
The main factors facilitating implementation of MDA for LF programmes were awareness creation through innovative community health education programmes, creation of partnerships and collaborations, integration with existing programmes, creation of morbidity management programmes, motivation of community drug distributors (CDDs) through incentives and training, and management of adverse effects. Barriers to implementation included the lack of geographical demarcations and unregistered migrations into rapidly urbanizing areas, major disease outbreaks like the Ebola virus disease in West Africa, delayed drug deliveries at both country and community levels, inappropriate drug delivery strategies, limited number of drug distributors and the large number of households allocated for drug distribution.
Mass drug administration for lymphatic filariasis elimination programmes should design their implementation strategies differently based on specific contextual factors to improve implementation outcomes. Successfully achieving this requires undertaking formative research on the possible constraining and inhibiting factors, and incorporating the findings in the design and implementation of MDA for LF.
了解围绕淋巴丝虫病群体服药(MDA 防治 LF)消除计划实施过程的因素,对于成功实施类似干预措施至关重要。撒哈拉以南非洲(SSA)地区该病患病率位居世界第二,因此多个国家已启动并实施 MDA 防治 LF。系统评价主要聚焦于影响覆盖率和依从性的因素,而对 MDA 防治 LF 活动的实施关注较少。因此,本综述旨在记录撒哈拉以南非洲地区实施 MDA 防治 LF 的促进因素和障碍。
对数据库 PubMed、Science Direct 和 Google Scholar 进行系统检索。纳入分析的是 2000 年至 2016 年期间聚焦于 MDA 防治 LF 实施情况的英文同行评审出版物。通过主题分析,我们综合了最终的 18 篇文章,以确定 MDA 防治 LF 计划实施的关键促进因素和障碍。
促进 MDA 防治 LF 计划实施的主要因素包括通过创新的社区健康教育计划提高认识、建立伙伴关系与合作、与现有计划整合、建立发病管理计划、通过激励和培训激发社区药品分发员(CDD)的积极性以及不良反应管理。实施障碍包括缺乏地理划分以及向快速城市化地区的未登记移民、西非埃博拉病毒病等重大疾病暴发、国家和社区层面药品交付延迟、不适当的药品交付策略、药品分发员数量有限以及分配给药品分发的大量家庭。
淋巴丝虫病消除计划的群体服药应根据具体背景因素设计不同的实施策略,以改善实施效果。要成功实现这一点,需要对可能的制约因素进行形成性研究,并将研究结果纳入 MDA 防治 LF 的设计和实施中。